Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656734 · ClinicalTrials.gov registry record · Phase 1
Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00656734 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 27 participants.
The verdict
NCT00656734, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
To determine the highest and safest tolerated dose of MDX-1411 for the treatment of clear cell renal cell carcinoma (Kidney cancer).
Interventions
- BIOLOGICAL MDX 1411
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00656734
The ClinicalTrials.gov registry entry for NCT00656734 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MDX 1411 is the first listed.
NCT00656734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00656734 about?
NCT00656734 is a clinical study titled "Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.". To determine the highest and safest tolerated dose of MDX-1411 for the treatment of clear cell renal cell carcinoma (Kidney cancer).
What is the current status of trial NCT00656734?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2008-04. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00656734?
The interventions under investigation include: MDX 1411 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00656734?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.